natgillin/translations-raw huggingface dataset:
Also, up to 74% of patients treated with Keytruda lived for at least 12 months after the start of their treatment compared with 59% of patients on ipilimumab. 
Prav tako je po začetku zdravljenja v skupini bolnikov, ki so prejemali zdravilo Keytruda, do 74 % bolnikov živelo vsaj 12 mesecev, v skupini z ipilimumabom pa je bilo takih bolnikov 59 %.
Keytruda contains the active substance pembrolizumab. 
Zdravilo Keytruda vsebuje učinkovino pembrolizumab.
In a second study of 370 patients who could not be treated with cisplatin-containing medicines, Keytruda produced a complete or partial remission (clearing) of the cancer in 108 patients (29%); a complete remission occurred in 30 (8%) of them, meaning they no longer had any signs of cancer. 
V glavni študiji s 370 bolniki, ki niso mogli prejemati zdravil s cisplatinom, je zdravilo Keytruda delno ali v celoti uničilo raka pri 108 bolnikih (29 %).
In a main study of 210 patients, Keytruda produced a complete or partial remission (clearing) of the cancer in 145 patients (69%); a complete remission occurred in 47 (22%) of them, meaning they no longer had any signs of cancer. 
V glavni študiji z 210 bolniki je zdravilo Keytruda delno ali v celoti uničilo raka pri 145 bolnikih (69 %).
In addition, patients taking Keytruda alone lived on average 12.3 months compared with 10.3 months for patients taking other standard treatments. 
Poleg tega so bolniki, ki so jemali zdravilo Keytruda kot samostojno zdravilo, v povprečju živeli 12,3 meseca, bolniki, ki so prejemali druga standardna zdravljenja, pa 10,3 meseca.
Patients in the Keytruda group lived on average for around 6 months without their disease getting worse compared with 4.8 months for patients in the placebo group. 
Bolniki, ki so prejemali zdravilo Keytruda, so živeli povprečno šest mesecev brez poslabšanja bolezni, v primerjavi s 4,8 meseca pri bolnikih iz skupine, ki je prejemala placebo.
In a study looking at around 1,000 previously treated patients, patients lived longer with Keytruda given alone (around 11 months) than with another cancer medicine called docetaxel (around 8 months) and the period during which the disease did not get worse was around 4 months with both treatments. 
V študiji, v katero je bilo vključenih približno 1 000 predhodno zdravljenih bolnikov, so bolniki, ki so jemali samo zdravilo Keytruda, živeli dlje (približno 11 mesecev) kot tisti, ki so jemali drugo zdravilo za zdravljenje raka, docetaksel (približno osem mesecev).
Keytruda is also effective in improving survival of patients with renal cell cancer. 
Zdravilo Keytruda je bilo učinkovito tudi pri podaljševanju preživetja bolnikov z rakom ledvičnih celic.
Patients taking the Keytruda combination lived on average for 13.6 months compared with 10.4 months for patients taking other standard treatments. 
Bolniki, ki so prejemali zdravilo Keytruda v kombinaciji z navedeno kemoterapijo, so v povprečju živeli 13,6 meseca, bolniki, ki so prejemali druga standardna zdravljenja, pa 10,4 meseca.
Kidney cancer 
Nedrobnocelični pljučni rak
In some patients, tumours have to produce a high level of PD-L1 for the medicine to be effective. 
Pri nekaterih bolnikih je zdravilo učinkovito samo, če njihovi tumorji tvorijo večje količine beljakovine PD-L1.
In a second lung cancer study of 305 patients whose tumours tested strongly for PD-L1 who had not been treated before, patients on Keytruda lived for around 10 months without their disease getting worse compared with 6 months in patients receiving platinum-based chemotherapy. 
V drugi študiji pljučnega raka, v katero je bilo vključenih 305 bolnikov, pri katerih so bile s preiskavo ugotovljene večje količine beljakovine PD-L1 v tumorjih in ki pred tem še niso bili zdravljeni, so bolniki,
Keytruda is a cancer medicine used to treat: 
Keytruda je zdravilo za zdravljenje raka, ki se uporablja za zdravljenje: • melanoma, tj. vrste kožnega raka;
--1 1 dose (0.5 ml) contains: 
--1 En odmerek (0,5 ml) vsebuje:
Recombinant lipidated fHbp (factor H binding protein) Produced in Escherichia coli cells by recombinant DNA technology Adsorbed on aluminium phosphate (0.25 milligram aluminium per dose) 
adsorbirano na aluminijev fosfat (0,25 milligramov aluminija na odmerek)
Neisseria meningitidis serogroup B fHbp subfamily B 
fHbp iz Neisseria meningitidis serološke skupine B, podskupina B
Neisseria meningitidis serogroup B fHbp subfamily A 
fHbp iz Neisseria meningitidis serološke skupine B, podskupina A
1 pre-filled syringe with needle 
1 napolnjena injekcijska brizga z iglo
The recommended dose is 0.14 mg per kilogram body weight, once a day for five days. 
Priporočeni odmerek je 0,14 mg na kilogram telesne mase enkrat dnevno pet dni.
The marketing authorisation was renewed on 14 April 2009. 
Dovoljenje za promet je bilo obnovljeno 14. aprila 2009.
In the main study, 97% of the patients had either complete or partial remission (60 out of 62), and 76% had complete remission (47 out of 62). 
V glavni študiji je 97 % bolnikov doseglo popolno ali delno remisijo (60 od 62), 76 % ji je doseglo popolno remisijo (47 od 62).
Because cladribine has been used for a number of years, the company presented data from the published literature. 
Ker se kladribin uporablja že več let, je družba predstavila podatke iz objavljene literature.
Other information about Litak: 
Druge informacije o zdravilu Litak:
The main measures of effectiveness were the numbers of patients who had complete and partial remission following treatment. 
Glavno merilo učinkovitosti je bilo število bolnikov s popolno oziroma delno remisijo po zdravljenju.
The most common side effects with Litak (seen in more than 1 patient in 10) are infections, pancytopenia or myelosuppression (low blood cell counts), purpura (bruising), immunosuppression (a weakened immune system), decreased appetite, headache, dizziness, abnormal breath and chest sounds, cough, nausea (feeling sick), vomiting, constipation, diarrhoea, rash, localised exanthema (skin eruptions), diaphoresis (excessive sweating), injection site reactions (pain and inflammation at the site of injection), fever, fatigue (tiredness), chills and asthenia (weakness). 
Najpogostejši neželeni učinki zdravila Litak (opaženi pri več kot 1 bolniku od 10) so okužbe, pancitopenija ali mielosupresija (nizka raven krvnih celic), purpura (podplutbe), imunosupresija (oslabljen imunski sistem), zmanjšan apetit, glavobol, omotica, nenormalni dihalni zvoki in zvoki iz prsnega koša, kašelj, navzeja (slabost), bruhanje, zaprtje, driska, izpuščaj, lokalni eksantem (površinsko vnetje kože), diaforeza (čezmerno znojenje), reakcije na mestu injiciranja (bolečine in vnetje na mestu injiciranja), povišana telesna temperatura, utrujenost, mrazenje in astenija (šibkost).
The European Commission granted a marketing authorisation valid throughout the EU for Litak to Lipomed GmbH on 14 April 2004. 
Evropska komisija je dovoljenje za promet z zdravilom Litak, veljavno po vsej Evropski uniji, odobrila družbi Lipomed GmbH dne 14. aprila 2004.
CdATP can also affect other cells, particularly other types of blood cell, which can cause side effects. 
CdATP lahko vpliva tudi na druge celice, zlasti druge vrste krvnih celic, kar lahko povzroči neželene učinke.
These results were similar to those seen in other published studies using intravenous cladribine and were better than results seen with alternative treatments such as interferon alfa and pentostatin. 
Ti rezultati so bili podobni rezultatom iz drugih objavljenih študij uporabe intravenskega kladribina ter boljši od rezultatov drugačnih oblik zdravljenja, kot sta interferon alfa in pentostatin.
The summary of opinion of the Committee for Orphan Medicinal Products for Litak is available here. 
Povzetek mnenja Odbora za zdravila sirote o zdravilu Litak je na voljo tukaj.
This prevents the cells from dividing, slowing down the progression of leukaemia. 
To prepreči deljenje celic in upočasni napredovanje levkemije.
It belongs to the group of anticancer medicines called ‘antimetabolites'. 
Spada v skupino zdravil proti raku, imenovano „antimetaboliti“.
Litak was not compared with any other treatments in this study. 
V tej študiji zdravila Litak niso primerjali z nobeno drugo vrsto zdravljenja.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) LITAK EPAR summary for the public 
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) LITAK Povzetek EPAR za javnost
What is the risk associated with Litak? 
Kakšna tveganja so povezana z zdravilom Litak?
What benefit has Litak shown during the studies? 
Kakšne koristi je zdravilo Litak izkazalo med študijami?
Patients can inject themselves once they have been trained appropriately. 
Bolniki si lahko po ustreznem usposabljanju zdravilo vbrizgavajo sami.
Cladribine has been in use in anticancer medicines since the 1980s and it has been available as an intravenous infusion (drip into a vein) in some European Union (EU) Member States since 1993. 
Kladribin se uporablja za zdravljenje raka od osemdesetih let, od leta 1993 pa je na voljo kot intravenska infuzija (kapalna infuzija v veno) v določenih državah članicah Evropske unije.
Complete remission is the disappearance of all evidence of disease, whereas partial remission is improved blood counts and the reduction in the number of cancerous cells. 
Popolna remisija je opredeljena kot odsotnost vseh znakov bolezni, delna remisija pa je opredeljena kot izboljšanje krvne slike in zmanjšanje števila rakastih celic.
Because the number of patients with hairy cell leukaemia is low, the disease is considered ‘rare', and Litak was designated an ‘orphan medicine' (a medicine used in rare diseases) on 18 September 2001. 
Ker je število bolnikov z dlakavocelično levkemijo majhno, velja ta bolezen za redko, zato je bilo zdravilo Litak dne 18. septembra 2001 določeno kot „zdravilo sirota” (zdravilo, ki se uporablja pri redkih boleznih).
Purine is one of the fundamental chemicals that make up DNA. 
Purin je ena od osnovnih kemijskih snovi, ki tvorijo DNK.
It should be used with caution in patients over 65 years of age, with frequent monitoring of blood counts, the liver and the kidneys. 
Previdno ga je treba uporabljati pri bolnikih, starejših od 65 let, in sicer s pogostim nadzorom števila krvnih celic, jeter in ledvic
Litak treatment should be started by a doctor who has experience in the use of cancer treatments. 
Zdravljenje z zdravilom Litak mora uvesti zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje rakavih obolenj.
The Committee recommended that Litak be given marketing authorisation. 
Odbor je priporočil, da se za zdravilo Litak odobri dovoljenje za promet.
Litak is used to treat adults with hairy cell leukaemia, a cancer of blood in which too many B-lymphocytes (a type of white blood cell) are produced. 
Zdravilo Litak se uporablja za zdravljenje odraslih z dlakavocelično levkemijo, vrsto krvnega raka, pri katerem nastaja preveč B-limfocitov (vrsta belih krvničk).
Litak is given as an injection under the skin. 
Zdravilo Litak se daje z injiciranjem pod kožo.
The term ‘hairy cell' refers to the hair-like projections that can be seen on the surface of the lymphocytes when they are examined under a microscope. 
Izraz „dlakavocelična” se nanaša na lasaste izrastke na površini limfocitov, ki so vidni pod mikroskopom.
Litak has been examined in one main study involving 63 adults with hairy cell leukaemia. 
Zdravilo Litak so raziskali v eni glavni študiji, v katero je bilo vključenih 63 bolnikov z dlakavocelično levkemijo.
Why has Litak been approved? 
Zakaj je bilo zdravilo Litak odobreno?
The Committee for Medicinal Products for Human Use (CHMP) decided that Litak's benefits are greater than its risks for the treatment of hairy cell leukaemia. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je sklenil, da so koristi zdravila Litak pri zdravljenje dlakavocelične levkemije večje od z njim povezanih tveganj.
Litak should not be used in people who may be hypersensitive (allergic) to cladribine or any of the other ingredients. 
Zdravila Litak ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) kladribin ali katero koli drugo sestavino zdravila.
Litak must not be used during pregnancy or breast-feeding, in patients less than 18 years of age, in patients with moderate to severe kidney or liver disease or in combination with other medicines that reduce the production of blood cells. 
Zdravila Litak ne smejo uporabljati nosečnice ali doječe matere, bolniki, mlajši od 18 let, bolniki z zmernim do hudim obolenjem ledvic ali jeter in bolniki, ki se zdravijo z drugimi zdravili, ki zavirajo nastajanje krvnih celic.
Cladribine is an ‘analogue' of purine (a substance that has a similar chemical structure to purine). 
Kladribin je analog purina (pomeni, da ima podobno kemijsko strukturo kot purin).
In the body, cladribine is converted within lymphocytes into a chemical called CdATP, which interferes with the production of new DNA. 
V limfocitih v telesu se kladribin pretvori v kemikalijo, imenovano CdATP, ki ovira nastajanje nove DNK.
For the full list of all side effects reported with Litak, see the Package Leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Litak, glejte navodilo za uporabo.
What is Litak used for? 
Za kaj se zdravilo Litak uporablja?
Litak must not be given to patients with moderate to severe liver or kidney disease. 
Zdravilo Litak se ne sme uporabljati pri bolnikih z zmernim do hudim obolenjem jeter ali ledvic.
How has Litak been studied? 
Kako je bilo zdravilo Litak raziskano?
The active substance in Litak, cladribine, is a cytotoxic, a medicine that kills cells that are dividing, such as cancer cells. 
Zdravilna učinkovina zdravila Litak, kladribin, je citotoksična, kar pomeni, da ubija celice, ki se delijo (npr. rakaste celice).
Litak is a solution for injection that contains the active substance cladribine. 
Zdravilo Litak je raztopina za injiciranje, ki vsebuje zdravilno učinkovino kladribin.
How is Litak used? 
Kako se zdravilo Litak uporablja?
The full EPAR for Litak can be found here. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Litak je na voljo tukaj.
How does Litak work? 
Kako zdravilo Litak deluje?
What is Litak? 
Kaj je zdravilo Litak?
London, 23 July 2008 Doc. 
London, 23. julij 2008 Dok.
The procedure started on 29 March 2007. 
Napotitveni postopek se je pričel 29. marca 2007.
Bipolar disorder 
Bipolarna motnja
A Decision was issued by the European Commission on 23 July 2008. 
Evropska komisija je odločbo sprejela 23. julija 2008.
Ref. EMEA/CHMP/212114/2008 
ref. EMEA/476648/2008
Adults and children above 12 years 
Odrasli in otroci, starejši od 12 let
The Marketing Authorisation Holder provided supplementary information on 16 October 2007. 
Imetnik dovoljenja za promet z zdravilom je 16. oktobra 2007 predložil dodatne potrebne podatke.
Children 2 to 12 years 
Otroci od 2 do 12 let
With respect to quality aspects, 
Vidik kakovosti
Adults 18 years and above 
Odrasli, stari 18 let in več
Lamictal and associated names, 25 mg, 50 mg, 100 mg, 200 mg tablet and 2 mg, 5 mg, 25 mg, 50 mg, 100 mg, 200 mg, dispersible / chewable tablet, is an antiepileptic drug, used for the treatment of epilepsy and Bipolar Disorder. 
Zdravilo Lamictal in z njim povezana imena, tablete v odmerkih po 25 mg, 50 mg, 100 mg, 200 mg ter disperzibilne/žvečljive tablete v odmerkih po 2 mg, 5 mg, 25 mg, 50 mg, 100 mg, 200 mg, je antiepileptik za zdravljenje epilepsije in bipolarne motnje.
The excipients used in the formulations of the drug product and manufacturing processes are standard for the proposed pharmaceutical forms. 
Uporabljene pomožne snovi v pripravkih zdravila in proizvodni proces so za predlagane farmacevtske oblike standardni.
The results indicate that the drug substance and drug product can be reproducibly manufactured. 
Rezultati kažejo, da se lahko učinkovine in zdravilo ustrezno ponovljivo proizvajajo.
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 30 REFERRAL FOR Lamictal and associated names International Non-Proprietary Name (INN): lamotrigine 
ODBOR ZA ZDRAVILA ZA UPORABO V HUMANI MEDICINI (CHMP) MNENJE V ZVEZI Z NAPOTITVIJO V SKLADU S ČLENOM 30 ZA ZDRAVILO Lamictal in z njim povezana imena Mednarodno nelastniško ime (INN): lamotrigin
The drug substance and the drug product have been appropriately described and generally satisfactory documentation has been provided. 
Učinkovine in zdravilo so bili primerno opisani, predložena pa je bila tudi ustrezna dokumentacija.
Lamictal is indicated for the prevention of mood episodes in patients with bipolar disorder, predominantly by preventing depressive episodes. 
Zdravilo Lamictal je indicirano za preprečevanje razpoloženjskih epizod pri bolnikih z bipolarnimi motnjami, predvsem za preprečevanje depresivnih epizod.
On 1 March 2007, GlaxoSmithKline Research & Development Limited presented to the EMEA a referral under Article 30 of Directive 2001/83/EC, as amended, in order to harmonise the nationally authorised Summaries of Product Characteristics (SPC), Labelling and Package Leaflet including quality aspects of the medicinal product Lamictal and associated names. 
Družba GlaxoSmithKline Research & Development Limited je 1. marca 2007 pri Evropski agenciji za zdravila (EMEA) sprožila napotitveni postopek v skladu s členom 30 Direktive 2001/83/ES, kakor je bila spremenjena, za uskladitev nacionalno odobrenih povzetkov glavnih značilnosti zdravila (SPC), označevanj in navodil za uporabo, vključno z vidikom kakovosti zdravila Lamictal in z njim povezanih imen.
During its 21 - 24 April 2008 meeting, the CHMP, in the light of the overall submitted data and the scientific discussion within the Committee, was of the opinion that the proposal for the harmonisation of the SPC, Labelling and Package leaflet including the quality aspects was acceptable and that they should be amended. 
Med zasedanjem od 21. do 24. aprila 2008 je CHMP ob upoštevanju vseh predloženih podatkov in strokovne razprave v Odboru menil, da je predlog za uskladitev povzetkov glavnih značilnosti zdravil, označevanja in navodila za uporabo, vključno z vidikom kakovosti, sprejemljiv ter da jih je treba dopolniti.
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II together with the amended SPC, Labelling and Package Leaflet in Annex III. 
Seznam zadevnih imen zdravila je naveden v Dodatku I. Znanstveni zaključki so podani v Dodatku II, dopolnjeni povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo pa v Dodatku III.
After epileptic control has been achieved during adjunctive therapy, concomitant antiepileptic drugs (AEDs) may be withdrawn and patients continued on Lamictal monotherapy. 
Po vzpostavitvi nadzora nad epilepsijo med dodatno terapijo se lahko zdravljenje z drugim, sočasno uporabljenim antiepileptikom prekine, bolnik pa nadaljuje monoterapevtsko zdravljenje z zdravilom Lamictal.
The CHMP gave a positive opinion on 24 April 2008 recommending the harmonisation of the SPC, Labelling and Package Leaflet including quality aspects for Lamictal and associated names. 
Odbor za zdravila za uporabo v humani medicini je dne 24. aprila 2008 izdal pozitivno mnenje, s katerim je priporočil uskladitev povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo, vključno z vidikom kakovosti za zdravilo Lamictal in z njim povezana imena.
Lamictal is indicated for use as adjunctive or monotherapy in the treatment of epilepsy, for partial seizures and generalised seizures, including tonic-clonic seizures and the seizures associated with Lennox-Gastaut Syndrome. 
Zdravilo Lamictal je indicirano kot dodatno zdravljenje ali monoterapija za zdravljenje epilepsije za delne ali generalizirane napade, vključno s tonično-kloničnimi napadi in napadi, povezanimi s sindromom Lennox-Gastaut.
Lamictal is indicated as adjunctive therapy in the treatment of epilepsy, for partial seizures and generalised seizures including tonic-clonic seizures and the seizures associated with Lennox-Gastaut Syndrome. 
Zdravilo Lamictal je indicirano kot dodatna terapija za zdravljenje epilepsije za delne ali generalizirane napade, vključno s tonično-klončnimi napadi in napadi, povezanimi sindromom Lennox-Gastaut.
The basis for referral was that there were divergences in the Summaries of Product Characteristics (SPC) including quality aspects of Lamictal and associated names approved across EU Member States, with respect to the indication, 
Napotitev temelji na neskladjih v povzetkih glavnih značilnosti zdravila med državami članicami EU, vključno z vidikom kakovosti zdravila Lamictal in z njim povezanih imen v zvezi z naslednjimi indikacijami:
This overview was last updated in December 2018. 
Pregled je bil nazadnje posodobljen decembra 2018.
This will help protect against coccidiosis. 
To jim bo pomagalo pri zaščiti pred kokcidiozo.
Evant received a marketing authorisation valid throughout the EU on 5 February 2019. 
Zdravilo Evant je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 5. februarja 2019.
Further information on Evant can be found on the Agency's website: ema.europa.eu/Find medicine/veterinary/EPAR/evant. 
Nadaljnje informacije o zdravilu Evant so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/veterinary/EPAR/evant.
Protection starts at 2 weeks after vaccination and lasts until 9 weeks after vaccination. 
Zaščita začne delovati dva tedna po cepljenju in traja do devet tednov po cepljenju.
The European Medicines Agency decided that Evant's benefits are greater than its risks and it can be authorised for use in the EU. 
Evropska agencija za zdravila je zaključila, da so koristi zdravila Evant večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Other information about Evant 
Druge informacije o zdravilu Evant
Evant (avian coccidiosis vaccine, live) 
Evant (cepivo proti aviarni kokcidiozi, živo)
The vaccine suspension should be diluted with the solvent and water according to dosing instructions and sprayed on the birds so that each bird receives one dose. 
Suspenzijo cepiva je treba razredčiti z vehiklom in vodo po navodilih za odmerjanje ter jo razpršiti po ptičih, tako da vsak ptič prejme en odmerek.
Evant is a vaccine. 
Zdravilo Evant je cepivo.
Evant (avian coccidiosis vaccine, live) EMA/893808/2018 
Evant (cepivo proti aviarni kokcidiozi, živo) EMA/893808/2018
What benefits of Evant have been shown in studies? 
Kakšne koristi je zdravilo Evant izkazalo v študijah?
An overview of Evant and why it is authorised in the EU 
Pregled zdravila Evant in zakaj je odobreno v EU
In the future if the animals are exposed to the same Eimeria species the immune system will be able to respond more quickly. 
Ob ponovni izpostavitvi živali parazitom vrste Eimeria v prihodnosti se bo imunski sistem tako hitreje odzval.
What is Evant and what is it used for? 
Kaj je zdravilo Evant in za kaj se uporablja?
What are the risks associated with Evant? 
Kakšna tveganja so povezana z zdravilom Evant?
Why is Evant authorised in the EU? 
Zakaj je zdravilo Evant odobreno v EU?
The vaccine is given to chicks from one day old. 
Cepivo se daje piščancem od prvega dne starosti dalje.
The vaccine solvent contains the adjuvant montanide IMS to enhance the immune response. 
Vehikel cepiva vsebuje tudi dodatek montanid IMS za povečanje imunskega odziva.
The withdrawal period for meat and eggs from chickens treated with Evant is ‘zero' days, which means that there is no mandatory waiting time. 
Karenca za meso in jajca piščancev, zdravljenih z zdravilom Evant, je nič dni, kar pomeni, da ni obvezne čakalne dobe.
Evant is available as a suspension and solvent and can only be obtained with a prescription. 
Zdravilo Evant je na voljo v obliki suspenzije in vehikla ter se predpisuje in izdaja le na recept.
The birds ingest the vaccine when preening their feathers. 
Ptice cepivo zaužijejo, ko si s kljunom čistijo perje.
These studies had a control group of chicks that received a dummy vaccination. 
V teh študijah je kontrolna skupina piščancev prejela navidezno cepivo brez učinkovine.